Free PSA and percent free PSA: what the result means

Free PSA and bound PSA are two forms of one protein

PSA is an enzyme made by prostate tissue. Once it reaches the bloodstream, most of it is captured by a blood protein called alpha-1-antichymotrypsin. That captured form is bound, or complexed, PSA. The remainder circulates on its own and is called free PSA. A standard PSA test reports the two together as total PSA.

In 1991, research groups in Finland and Sweden showed that bound PSA is the predominant form in blood, and that the bound share is higher in men with prostate cancer than in men with benign enlargement. The reverse reading is the one used in clinic: the smaller the free share, the more concern. Why cancer shifts the balance is not fully settled, and the test does not depend on the explanation. It depends on the pattern seen in biopsy studies.

How percent free PSA is calculated

Divide the free PSA by the total PSA from the same blood draw and multiply by 100. A free PSA of 0.9 ng/mL with a total PSA of 6.0 ng/mL is 0.9 ÷ 6.0 = 0.15, or 15% free PSA. Both values must come from the same sample and the same laboratory method.

A free PSA concentration has no meaning alone. A free PSA of 1.2 ng/mL is 30% of a total PSA of 4.0 ng/mL and 12% of a total PSA of 10.0 ng/mL, and those two percentages fall in opposite risk bands. If the report lists free PSA without a percentage, the arithmetic can be done by hand, but the published tables apply only when total PSA is between 4.0 and 10.0 ng/mL.

When the test is meant to be used

Free PSA was validated for a narrow question: a man aged 50 or older, a total PSA between 4.0 and 10.0 ng/mL, and a rectal examination that does not feel suspicious. That range is sometimes called the diagnostic gray zone, because total PSA alone separates cancer from benign enlargement poorly there. The National Cancer Institute notes that only about 25% of men who have a biopsy because of an elevated PSA are found to have prostate cancer.

Outside that range the test adds less. Mayo Clinic Laboratories notes that below 2.0 ng/mL the probability of cancer in a man without symptoms is low and free PSA may add little, and that above 10.0 ng/mL the probability is high enough that the total PSA usually drives the decision.

The range from 2.6 to 4.0 ng/mL has been studied as well. In a screening study of men in that range with a benign examination, cancer was found in 22% of the 332 who had a biopsy, and a cutoff of 27% or less would have detected 90% of those cancers while avoiding 18% of benign biopsies. A later review of 66 studies found the ratio performs significantly worse in the 2 to 4 range than in the 4 to 10 range.

Percent free PSA by age: the probability table laboratories print

Many U.S. lab reports carry the table below. It gives the probability of finding prostate cancer on needle biopsy for men whose total PSA is between 4.0 and 10.0 ng/mL, grouped by free-to-total ratio and by age. These are the figures published in the Mayo Clinic Laboratories test catalog. Within every ratio band the probability rises with age, which is why age belongs in the reading.

The underlying evidence is the 1998 multicenter trial: 773 men aged 50 to 75 at seven university centers, all with total PSA 4.0 to 10.0 ng/mL and a palpably benign gland. Across that group, individual risk ran from 8% at the highest percent free PSA to 56% at the lowest.

Two limits apply. The studies were run in the 1990s, before prostate MRI was part of the pathway, and they counted any cancer found on biopsy rather than only higher-grade cancer. The table also describes groups of men. It cannot say which individual in a band has cancer.

One total PSA, four different free PSA results

Take a 64-year-old with a confirmed total PSA of 6.0 ng/mL and a normal examination. The total PSA is the same in all four cases below. Only the free PSA changes, and the table reading moves from 58% to 12%.

The bands are wide and the edges are abrupt. A free PSA of 1.5 ng/mL sits at exactly 25%, and 1.6 ng/mL moves to the lowest band, a difference smaller than normal variation between two blood draws. That is the reason a percent free PSA near a cutoff is often repeated or read beside other information instead of being treated as a verdict.

What the 25% and 10% cutoffs can and cannot do

In the 1998 trial, recommending biopsy at 25% free PSA or less detected 95% of cancers and avoided 20% of unnecessary biopsies. Read the other way, 5% of cancers sat above the cutoff. The authors reported that those cancers were more common in older men and were generally less threatening in grade and volume, but they were cancers.

The cost of keeping sensitivity that high is low specificity. Pooled across 66 studies, at 95% sensitivity the ratio correctly cleared 18% of men without cancer in the 4 to 10 ng/mL range, and 6% in the 2 to 4 range. Most men without cancer still fall below the cutoff.

The 10% line marks the highest-probability band in the table, not a diagnosis. At age 60 to 69 it corresponds to a 58% chance of cancer on biopsy. Mayo Clinic Laboratories states plainly that normal results do not eliminate the possibility of prostate cancer, and that up to 20% of men with a negative biopsy have later been found to have cancer.

What can shift a free PSA result besides cancer

Prostate size. Benign enlargement raises total PSA and tends to raise the free share with it. In a 1995 study of men with total PSA 4.1 to 10.0 ng/mL, median percent free PSA was 9.2% in men with cancer and a normal-sized gland, 15.9% in men with cancer and an enlarged gland, and 18.8% in men with benign enlargement alone. A large gland can mask a low ratio, which is one reason prostate volume and PSA density are read alongside it.

Sample handling. Free PSA is less stable in the tube than total PSA. Mayo Clinic Laboratories instructs that serum be separated within three hours of collection and accepts refrigerated samples for 72 hours. A 2024 laboratory study of serum from 45 men found total PSA stable in storage while free PSA declined, with the ratio holding for 72 hours before it fell. A delayed sample biases the percentage downward, toward a more worrying reading.

Laboratory method. Results from different assay kits are not interchangeable. Free and total PSA should be run on the same platform, and a change of laboratory between tests can move the percentage without any change in the prostate. Recent prostate biopsy or transurethral surgery can also raise PSA results, so blood is drawn before those procedures.

Finasteride and dutasteride. These medicines lower total PSA by about half. In a randomized trial, mean total PSA fell from 3.0 to 1.5 ng/mL after six months of finasteride while percent free PSA did not change significantly, and a second study found free and total PSA fell about equally. The practical points: tell the clinician about the medicine, because the total PSA needs adjustment, and know that the 4 to 10 ng/mL condition attached to the probability table refers to the measured total PSA.

Where free PSA sits beside PSA density, PHI, 4Kscore, and MRI

Free PSA was the first widely used second-line blood marker, and it is built into two newer ones. The Prostate Health Index combines total PSA, free PSA, and a free PSA subform called [-2]proPSA; it was evaluated in 892 men with total PSA 2 to 10 ng/mL and a normal examination. The 4Kscore combines four related blood markers, free PSA among them, with clinical information; it was evaluated in 1,012 men at 26 U.S. centers. Both were designed to estimate the chance of higher-grade cancer, which the original free PSA studies did not isolate.

The AUA/SUO early-detection guideline does not name one marker as the required next step. Its statement is that clinicians may use adjunctive urine or serum markers when further risk stratification would influence the decision whether to proceed with biopsy, graded as a conditional recommendation on Grade C evidence. The 2026 amendment updates the discussion of available biomarkers. The guideline also recommends confirming a newly elevated PSA before moving to any second-line test.

In practice the choice depends on what is already known. If prostate volume has been measured, PSA density uses it directly. If MRI is planned or done, its findings carry their own weight in the biopsy decision. Free PSA remains widely available and inexpensive, and it can be run on the same sample as the repeat PSA. Which combination fits is a question for the clinician who knows the examination, the history, and the prior values.

Turning the number into a plan

A percent free PSA result is one input to a biopsy decision. It is weighed with age, the total PSA and its trend, prostate size, the examination, family and inherited risk, medicines, prior biopsies, MRI findings when available, and overall health. A low percentage in a man with a small gland and a rising total PSA reads differently from the same percentage on a sample that waited a day before processing.

Whatever the number, the useful outcome of the visit is a written next step with a date: repeat the test under good conditions, add volume or imaging, proceed to biopsy, or monitor on a defined schedule with a trigger for earlier review. Fever with urinary symptoms, inability to urinate, or severe pain needs prompt medical attention regardless of any PSA value.